

Anti-Inflammatory Herbs in Rheumatoid Arthritis: Mechanistic In Vitro Studies and Translational Potential

Sivasubramanian P^{1*}, Harini G¹, Kamali S¹, Harish. V¹, Isaiamuthan.M¹

¹SNS College of Pharmacy and Health Sciences, Coimbatore, Pin: 641035

*Corresponding Author E-mail: yuccasiva@gmail.com

ABSTRACT

Key anti-inflammatory herbal compounds—curcumin, curcumin analogues, resveratrol, boswellic acids derived from *Boswellia serrata*, and *Tripterygium wilfordii* extracts—are reviewed in this study, together with mechanistic in vitro data and translational implications, for the management of rheumatoid arthritis (RA). This research provides a summary of their molecular processes, which include cytokine suppression, NF- κ B inhibition, antioxidant action, and immunological modulation, based solely on recent systematic reviews, meta-analyses, preclinical evaluations, and randomized trials. Emerging clinical translation in autoimmune illnesses and osteoarthritis is supported by good molecular evidence for these herbs, especially curcumin, resveratrol, and boswellic acids. Bioavailability, consistent dosage, and long-term safety are still areas where research is lacking in RA. Optimized formulations, high-quality RA-specific clinical studies, and mechanistic validation through in vitro disease models should be the priorities of future research.

Key Words:

Rheumatoid arthritis, Anti-inflammatory herbs, Curcumin, Resveratrol, *Boswellia serrata*

Article History:

Received Sep 01, 2025

Revised Oct 21, 2025

Accepted Nov. 11, 2025

Published Oct 10, 2025

DOI: <https://doi.org/10.64063/3049-1630.vol.2.issue11.1>

1. INTRODUCTION

Joint degeneration, oxidative stress, and ongoing inflammation are hallmarks of the complicated autoimmune disease known as rheumatoid arthritis (RA). The management of disease has been greatly improved by conventional medications, yet many patients still face side effects, poor therapeutic response, and heavy financial burdens. Consequently, there has been a surge of interest in herbal substances with anti-inflammatory properties due to their ability to control important inflammatory pathways associated with RA. Natural bioactives like curcumin, resveratrol, boswellic acids, and *Tripterygium wilfordii* extracts may provide mechanistically strong, multi-targeted therapeutic effects, according to emerging in vitro, in vivo, and clinical data. In this section, we will go over the scientific background, goals, and relevance of studying these herbal compounds in relation to the pathophysiology of RA.

1.1. Background and Context

A systemic inflammatory illness known as rheumatoid arthritis (RA) causes constant inflammation of the synovium, which in turn causes oxidative stress and the gradual degeneration of joints. RA can severely limit a person's mobility and quality of life. Despite the significant improvement in disease control achieved with conventional therapy alternatives such as DMARDs, biologic medicines, and JAK inhibitors, their usage is frequently hindered by side effects, expensive treatment costs, and unpredictable patient tolerance. Due to these limitations, there has been a growing interest in natural anti-inflammatory herbs that have been clinically proven to have therapeutic effects, especially those that can modulate important pathways associated with rheumatoid arthritis, such as those involving oxidative stress, immunological dysregulation, and pro-inflammatory cytokines. There is mounting evidence that bioactive compounds derived from *Tripterygium wilfordii*, including curcumin, resveratrol, boswellic acids, and others, can suppress inflammatory mediators, reduce oxidative stress, inhibit synovial hyperplasia, and exert multi-targeted immunomodulatory effects; these benefits could have translational implications for the treatment of rheumatoid arthritis.

1.2. Objectives of the Review

- To summarize mechanistic in vitro evidence of major anti-inflammatory herbs implicated in RA.
- To evaluate methodologies and findings of key preclinical and clinical studies.
- To synthesize thematic insights regarding pathways, efficacy, and translational potential.
- To identify gaps and propose future research priorities.

1.3. Importance of the Topic

High-burden autoimmune illnesses such as rheumatoid arthritis demand therapeutic options that are not only efficacious but also safer, more accessible, and capable of targeting the complex network of inflammatory and immunological pathways involved in disease progression. Given the limits of current therapies—including unpleasant effects, high costs, and inconsistent patient responsiveness—there is an increasing need to seek complementary approaches that offer mechanistic depth and translational promise. In this context, a focused examination of herbal anti-inflammatory mechanisms becomes highly significant, as it provides a scientific basis for integrating natural compounds into evidence-based therapeutic frameworks, supports the development of synergistic or alternative treatment strategies, and guides future drug discovery efforts rooted in validated molecular and cellular actions.

2. RESULT AND FINDINGS

The bulk of this review compiles the data on the anti-inflammatory effects of some herbal substances in RA, both from a mechanistic and translational perspective. Research on curcumin and its derivatives, resveratrol, *Boswellia serrata* extracts, and *Tripterygium wilfordii* Hook F. has been conducted through systematic reviews, meta-analyses, preclinical studies, and clinical trials.

The results have been organized into thematic categories in this section. Each subsection delves into the molecular mechanisms, methodological approaches, experimental outcomes, and comparative strengths and limitations of the respective research. This part emphasizes the biological relevance and clinical plausibility of these herbs in lowering RA-related inflammation by analyzing both in vitro and translational research.

Curcumin and Curcumin Derivatives

- **Mechanistic Insights**

Review after review has shown that curcumin has the ability to target many inflammatory pathways, making it an attractive candidate for the treatment of rheumatoid arthritis. The inflammatory cascade that causes synovial hyperplasia and joint deterioration can be mitigated by curcumin since it consistently suppresses important pro-inflammatory cytokines such IL-1 β , TNF- α , and IL-6. Curcumin not only has an impact on cytokine levels, but it also inhibits key intracellular signaling pathways like NF- κ B, MAPK, and JAK/STAT. These pathways are essential for controlling the growth of synoviocytes and the state of the immune system. In addition to reducing inflammation and injury in RA synovium, its potent antioxidant capabilities can slow disease development. In addition, new curcumin analogues have been developed thanks to developments in curcumin chemistry. These analogues have better cell permeability, increased bioavailability, and greater molecular stability, making them more effective and lasting in their pharmacological effects than native curcumin.

- **Study Findings**

In a meta-analysis and systematic review¹ found that clinical symptoms and inflammatory markers improved. A study conducted by Liu et al. (2025)² showed that curcumin can regulate many inflammatory pathways. This finding could be useful for treating disorders related to the immune system. Synthetic curcumin analogues exhibit enhanced anti-inflammatory activity in vitro, according to Kaur et al. (2024)³. Bisdemethoxycurcumin is found to greatly reduce arthritic symptoms by preventing the migration of macrophages, according to research by Sun et al. (2024)⁴.

- **Strengths and Weaknesses**

Strengths: Strong mechanistic consistency across pathways. Multiple systematic reviews validate findings. Derivatives overcome curcumin's natural bioavailability limitations.

Weaknesses: Limited RA-specific human trials. Considerable variability in formulations and dosages. Need for standardization in in vitro experiments.

Resveratrol

- **Mechanistic Insights**

Resveratrol has the ability to modulate the immune system and reduce inflammation in rheumatoid arthritis due to its complex network of biological effects. The downregulation of important pro-inflammatory cytokines and the considerable suppression of NF- κ B signaling are two of its main impacts (Sheng et al., 2022)⁵. The former is a fundamental route that drives chronic synovial inflammation and the latter leads to joint degeneration. In addition to suppressing cytokines,

resveratrol is involved in immunological modulation through restoring T-cell balance, which helps to counteract the dysregulated immune responses seen in RA. Further reducing oxidative stress and protecting synovial tissues from damage caused by reactive oxygen species, it exerts its high antioxidant effect mainly through the activation of the Nrf2 pathway (de Carvalho & Lerner, 2023)⁶. Furthermore, new information about resveratrol's predicted interactions with various molecular targets related to RA has been uncovered by recent AI-assisted analyses and network pharmacology models. This information suggests that resveratrol may have a mechanistic impact on processes like synovial hyperplasia, oxidative injury, and cartilage destruction (Zeng et al., 2024)⁷.

- **Study Findings**

- ❖ Sheng et al. (2022) demonstrated translational promise from in vitro data to clinical contexts.
- ❖ de Carvalho & Lerner (2023) synthesized evidence across rheumatological diseases, supporting systemic anti-inflammatory benefits.
- ❖ Zeng et al. (2024) combined bioinformatics, network pharmacology, and AI to predict mechanistic targets specific to RA.

- **Strengths and Weaknesses**

Strengths: Broad-spectrum anti-inflammatory effects. Emerging computational validation of RA-related pathways. Extensive preclinical backing.

Weaknesses: Limited direct RA clinical trials. High-dose requirement due to rapid metabolism. Variable purity of resveratrol supplements.

Boswellia serrata and Boswellic Acids

- **Mechanistic Insights**

The anti-inflammatory and anti-arthritis properties of *Boswellia serrata* and its active components, especially 3-acetyl-11-keto- β -boswellic acid (AKBA), have been extensively studied and support their use in rheumatoid arthritis. An important process that contributes to the maintenance of chronic inflammation and joint pain is the suppression of 5-lipoxygenase (5-LOX), an enzyme that is crucial for leukotriene production (Sakshi Priya & Singhvi, 2023)⁸. Boswellia chemicals work by blocking this route, which in turn decreases the influx of white blood cells into inflammatory joints, the release of pro-inflammatory cytokines, and the destruction of connective and cartilage tissues. Furthermore, there is mounting evidence that when combined with other phytochemicals, especially curcumin, Boswellia extracts have even more potent therapeutic effects. Mamatha et al. (2025)⁹ observed that these synergistic formulations enhance bioavailability and result in higher reductions in pain, stiffness, and inflammatory biomarkers. Taken as a whole, these molecular findings demonstrate the specific and complex function of Boswellia in regulating inflammatory processes linked to RA.

- **Study Findings**

- ❖ Majeed et al. (2024)¹⁰ demonstrated rapid improvements in osteoarthritis (within 5 days), supporting Boswellia's translational potential toward inflammatory joint diseases.
- ❖ Mamatha et al. (2025) observed significant reduction in pain and stiffness with a full-spectrum extract.
- ❖ Sakshi Priya & Singhvi (2023) highlighted AKBA's targeted anti-arthritic mechanisms specific to RA.

- **Strengths and Weaknesses**

Strengths: Active compounds well characterized. Increasing clinical evidence supporting safety and efficacy. Synergistic formulations promising for RA.

Weaknesses: Most clinical trials focus on osteoarthritis, not RA. Variability in extract standardization. Need for more in vitro RA synoviocyte-focused studies.

Tripterygium wilfordii Hook F. (TwHF)

- **Mechanistic Insights**

Tripterygium wilfordii Hook F. (TwHF) is an attractive herbal option for the treatment of rheumatoid arthritis due to its wide range of powerful immunosuppressive and anti-inflammatory effects. Its main function is to reduce the immune-driven inflammatory cascade that is essential to the development of RA by inhibiting T-cell activation and important pro-inflammatory cytokines (Shan et al., 2023). The proliferation of synovial fibroblasts, the cells responsible for pannus development and joint deterioration, is reduced by TwHF, which is a key regulator of synovial disease. The wide-ranging therapeutic potential of TwHF has been further demonstrated by recent advances in network pharmacology, which have linked its bioactive compounds to various molecular pathways associated with RA. These pathways include those that regulate the immune system, oxidative stress, and cytokine signaling (Mao & Xie, 2024)¹¹. Supporting its translational relevance and positioning it as one of the most biologically potent herbal interventions under investigation, meta-analytic evidence shows strong and consistent efficacy of TwHF extracts across numerous preclinical RA models, which is in line with these mechanistic findings (Chen et al., 2025)¹².

- **Study Findings**

- ❖ Shan et al. (2023)¹³ provided comprehensive mechanistic profiling and translational perspectives.
- ❖ Mao & Xie (2024) used molecular docking to identify binding interactions with key RA targets.
- ❖ Chen et al. (2025) consolidated preclinical evidence demonstrating strong anti-arthritic effects.

- **Strengths and Weaknesses**

Strengths: Strong preclinical efficacy. Broad immunomodulatory effect. Mechanistically mapped to multiple RA pathways.

Weaknesses: Concerns regarding toxicity at higher doses. Need for controlled clinical trials with standardized extracts. Most evidence remains preclinical.

3. DISCUSSION

To assess the anti-inflammatory herbs' potential as a treatment for RA, the discussion part synthesizes the main body's mechanistic topics and comparative findings. This section provides insight for how these natural substances impact essential pathways in RA development, including immunological, oxidative, and inflammatory, by analyzing areas of agreement and disagreement among research. In addition to highlighting the methodological constraints, gaps, and future research needs, the discussion delves into the practical significance of these findings for clinical translation.

3.1. Interpretation and Integration

Across all herbal agents, strong mechanistic convergence exists around:

- NF- κ B inhibition
- Reduction of pro-inflammatory cytokines
- Antioxidant pathways
- Suppression of synovial fibroblast activation
- Immune modulation

Curcumin and its analogues demonstrate the widest mechanistic coverage, whereas *Boswellia* offers targeted 5-LOX inhibition. Resveratrol bridges antioxidant and immunomodulatory effects, and TwHF provides powerful multi-target immune suppression.

3.2. Implications

- These herbs hold substantial translational promise as adjunct therapies.
- In vitro and preclinical data consistently demonstrate reduced inflammation and joint degradation.
- Optimized formulations (nanocarriers, analogues, synergistic combinations) significantly enhance therapeutic potential.

3.3. Gaps and Future Research

There is a clear need for more thorough and focused studies on anti-inflammatory herbal remedies for RA, since there are still many important gaps in the existing literature¹⁴. Before anything else, we need randomized controlled trials that specifically target RA to confirm the encouraging results from the mechanistic and preclinical studies that have been conducted so far. Inconsistent bioactive concentrations and unstandardized extract purity also make it difficult to compare results and develop trustworthy dosage recommendations¹⁵. Our knowledge of possible synergistic or alternative therapeutic functions is further constrained by the lack of comparative studies examining herbal medicines alongside recognized DMARDs. In addition, relevant questions regarding metabolism and safety remain unanswered due to inadequate long-term toxicity evaluations and thorough pharmacokinetic profiles. Future research should focus on doing

advanced in vitro investigations with RA synoviocyte models obtained from patients. These models are better able to mimic the disease milieu and can improve the applicability of the findings to translation.

4. CONCLUSION

The review's conclusion recaps its key points and muses on the bigger picture of herbal anti-inflammatory medicines' role in RA treatment. While recognizing the present constraints that prevent their broad clinical use, this section emphasizes the therapeutic promise of certain herbal substances by combining molecular information, preclinical outcomes, and forthcoming translational data. Additionally, it points the way for future studies that want to improve the efficacy, safety, and incorporation into RA care that is based on evidence.

Important anti-inflammatory herbs show great potential in the treatment of RA, according to this review, both in terms of mechanisms and translation. Research in vitro, in vivo, and early clinical studies have confirmed that curcumin, resveratrol, *Boswellia serrata* extracts, and *Tripterygium wilfordii* exhibit strong anti-inflammatory and immunomodulatory characteristics. Inadequate human studies, unstandardized formulations, and low bioavailability continue to impede clinical translation despite solid mechanistic foundations. Their multipath manner actions, however, point to great promise as supplementary treatments. Mechanistic validation of state-of-the-art in vitro disease platforms, rigorous clinical trials, and tailored formulations should be the focuses of future research

REFERENCES

1. Kou, H., Huang, L., Jin, M., He, Q., Zhang, R., & Ma, J. (2023). Effect of curcumin on rheumatoid arthritis: a systematic review and meta-analysis. *Frontiers in immunology*, 14, 1121655.
2. Liu, M., Wang, J., Song, Z., & Pei, Y. (2025). Regulation mechanism of curcumin mediated inflammatory pathway and its clinical application: a review. *Frontiers in Pharmacology*, 16, 1642248.
3. Kaur, K., Al-Khazaleh, A. K., Bhuyan, D. J., Li, F., & Li, C. G. (2024). A review of recent curcumin analogues and their antioxidant, anti-inflammatory, and anticancer activities. *Antioxidants*, 13(9), 1092.
4. Sun, X., Liang, Y., Wang, Y., Sun, C., & Wang, X. (2024). Bisdemethoxycurcumin, a curcumin derivative, ameliorates adjuvant-induced arthritis by suppressing inflammatory reactions and macrophage migration. *Chemico-Biological Interactions*, 387, 110822.
5. Sheng, S., Wang, X., Liu, X., Hu, X., Shao, Y., Wang, G., ... & Chen, X. (2022). The role of resveratrol on rheumatoid arthritis: From bench to bedside. *Frontiers in Pharmacology*, 13, 829677.
6. de Carvalho, J. F., & Lerner, A. (2023). Resveratrol in Rheumatological Diseases: A Systematic Review. *European journal of rheumatology*, 10(4), 163.

7. Zeng, P., Huang, H., & Li, D. (2024). Combining bioinformatics, network pharmacology, and artificial intelligence to predict the mechanism of resveratrol in the treatment of rheumatoid arthritis. *Heliyon*, 10(18).
8. Sakshi Priya & Gautam Singhvi (2023) Insights into the anti-inflammatory and anti-arthritic potential of 3-Acetyl-11-keto- β -Boswellic Acid as a therapeutic approach in Rheumatoid Arthritis, *Expert Opinion on Investigational Drugs*, 32:10, 867-871, DOI: 10.1080/13543784.2023.2269838
9. Mamatha, K., Prabhakaran, P., Syam Das, S., Kanjoormana Aryan, M., & Thomas, J. (2025). A full-spectrum *Boswellia serrata* extract with enhanced bioavailability, and its co-delivered system with curcumin alleviate pain and stiffness associated with moderate spondylitis: a randomized double-blind, placebo-controlled, 3-arm study. *Frontiers in Pharmacology*, 16, 1577429.
10. Majeed, A., Majeed, S., Satish, G., Manjunatha, R., Rabbani, S. N., Patil, N. V. P., & Mundkur, L. (2024). A standardized *Boswellia serrata* extract shows improvements in knee osteoarthritis within five days-a double-blind, randomized, three-arm, parallel-group, multi-center, placebo-controlled trial. *Frontiers in pharmacology*, 15, 1428440. <https://doi.org/10.3389/fphar.2024.1428440>
11. Mao, N., & Xie, X. (2024). Mechanisms of *Tripterygium wilfordii* Hook F on treating rheumatoid arthritis explored by network pharmacology analysis and molecular docking. *Open Medicine*, 19(1), 20240967.
12. Chen, K., Chen, X., Huang, S., Zhou, L., Zhou, X., Lu, Y., & Feng, Z. (2025). Therapeutic effects and mechanisms of *Tripterygium wilfordii* extracts in rheumatoid arthritis: a systematic review and meta-analysis of preclinical studies. *Scientific Reports*, 15(1), 27960.
13. Shan, Y., Zhao, J., Wei, K., Jiang, P., Xu, L., Chang, C., Xu, L., Shi, Y., Zheng, Y., Bian, Y., Zhou, M., Schrodi, S. J., Guo, S., & He, D. (2023). A comprehensive review of *Tripterygium wilfordii* hook. f. in the treatment of rheumatic and autoimmune diseases: Bioactive compounds, mechanisms of action, and future directions. *Frontiers in pharmacology*, 14, 1282610. <https://doi.org/10.3389/fphar.2023.1282610>
14. Li, J., Chen, L., Xu, X., Fan, Y., Xue, X., Shen, M., & Shi, X. (2020). Targeted combination of antioxidative and anti-inflammatory therapy of rheumatoid arthritis using multifunctional Dendrimer-Entrapped gold nanoparticles as a platform. *Small*, 16(49), 2005661.
15. Ramli, I., Cheriet, T., Posadino, A. M., Giordo, R., Zayed, H., Eid, A. H., & Pintus, G. (2023). Potential therapeutic targets of resveratrol in the prevention and treatment of pulmonary fibrosis.